DeGolyer Donald W 4
4 · Emergent BioSolutions Inc. · Filed May 4, 2026
Research Summary
AI-generated summary of this filing
Emergent BioSolutions Director Donald DeGolyer Sells Shares, Receives RSUs
What Happened
Donald W. DeGolyer, a director of Emergent BioSolutions (EBS), sold a total of 15,481 shares in open-market transactions and simultaneously received equity awards from the company. On May 1, 2026 he sold 14,527 shares at a weighted-average price of $8.36 (proceeds $121,446) and 954 shares at a weighted-average price of $8.96 (proceeds $8,548), for combined proceeds of $129,994. On April 30, 2026 he was granted 25,344 restricted stock units (RSUs) and 11,296 director stock options (both recorded at $0.00 in the filing). The sales were pursuant to a Rule 10b5-1 trading plan to satisfy tax obligations tied to RSU vesting.
Key Details
- Transaction dates: RSU/options grant recorded 2026-04-30; sales executed 2026-05-01; Form 4 filed 2026-05-04. Filing appears timely.
- Sale prices and ranges: 14,527 shares at $8.36 (weighted average; executed across $7.78–$8.64 per share) and 954 shares at $8.96 (weighted average; executed across $8.80–$8.99 per share). Total proceeds $129,994.
- Awards: 25,344 RSUs (vest on the day before the one‑year anniversary of the grant, subject to continued board service) and 11,296 stock options (vest on same annual schedule). Option count determined per company formula using Black‑Scholes value.
- Reason for sale: Shares sold under a pre-existing 10b5-1 plan to satisfy tax obligations related to RSU vesting (per footnote).
- Shares owned after transaction: Not specified in the provided filing.
- No indication of late filing or other irregularities in the Form 4.
Context
- The RSUs and options are director compensation and vest contingent on continued board service (routine annual grant).
- Sales under a 10b5-1 plan to cover tax withholding are common and generally considered routine rather than a direct signal of sentiment.
- Derivative award (options) are grants, not exercises—no immediate cash exercise occurred.
Insider Transaction Report
Form 4
DeGolyer Donald W
Director
Transactions
- Award
Common Stock
[F1]2026-04-30+25,344→ 145,202 total - Sale
Common Stock
[F2][F3]2026-05-01$8.36/sh−14,527$121,446→ 130,675 total - Sale
Common Stock
[F2][F4]2026-05-01$8.96/sh−954$8,548→ 129,721 total - Award
Stock Option (Right to Buy)
[F5][F6]2026-04-30+11,296→ 11,296 totalExercise: $7.99Exp: 2033-04-30→ Common Stock (11,296 underlying)
Footnotes (6)
- [F1]Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.
- [F2]Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated August 11, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026.
- [F3]The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $7.78 to $8.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F4]The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $8.80 to $8.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F5]Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.
- [F6]The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.
Signature
/s/ Richard S. Lindahl, Attorney-in-fact|2026-05-04